Assertio Holdings, Inc. (ASRT)
NASDAQ: ASRT · Real-Time Price · USD
0.813
+0.003 (0.35%)
At close: Feb 21, 2025, 4:00 PM
0.818
+0.005 (0.64%)
After-hours: Feb 21, 2025, 5:03 PM EST
Assertio Holdings Revenue
Assertio Holdings had revenue of $29.20M in the quarter ending September 30, 2024, a decrease of -18.03%. This brings the company's revenue in the last twelve months to $125.76M, down -25.77% year-over-year. In the year 2023, Assertio Holdings had annual revenue of $152.07M, down -2.67%.
Revenue (ttm)
$125.76M
Revenue Growth
-25.77%
P/S Ratio
0.61
Revenue / Employee
$2,372,887
Employees
53
Market Cap
77.60M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 152.07M | -4.17M | -2.67% |
Dec 31, 2022 | 156.23M | 45.22M | 40.73% |
Dec 31, 2021 | 111.01M | 2.94M | 2.72% |
Dec 31, 2020 | 108.08M | -121.45M | -52.91% |
Dec 31, 2019 | 229.53M | -26.54M | -10.36% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ASRT News
- 7 weeks ago - Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - GlobeNewsWire
- 2 months ago - Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - GlobeNewsWire
- 3 months ago - Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio - Business Wire
- 3 months ago - Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Assertio Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio - Business Wire
- 3 months ago - Assertio Provides Response to Letter from Short-seller - GlobeNewsWire